Who makes Benfotiamine 1050mg, 3 days?

Benfotiamine 1050mg, 3 days is developed by Ruhr University of Bochum.

What development phase is Benfotiamine 1050mg, 3 days in?

Benfotiamine 1050mg, 3 days is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Benfotiamine 1050mg, 3 days

Ruhr University of Bochum · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Benfotiamine 1050mg, 3 days
Sponsor	Ruhr University of Bochum
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Benfotiamine 1050mg, 3 days CI brief — competitive landscape report
Benfotiamine 1050mg, 3 days updates RSS · CI watch RSS
Ruhr University of Bochum portfolio CI